Results 61 to 70 of about 13,117,018 (331)
Вестник анестезиологии и реаниматологии, 2019 Goal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery. Methods.
N. A. TREKOVA +3 more
doaj +1 more source
PICALM::MLLT10 translocated leukemia
FEBS Letters, EarlyView.This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen +7 more
wiley +1 more source
Assessment of Factor VII Levels in Patients of Chronic Liver Disease
Journal of Rawalpindi Medical College, 2013 Background : To determine the levels of coagulation factor VII in patients of chronic liver disease. Methods: In this descriptive study sixty known patients of chronic liver disease were included.
Nabeela Naeem
doaj
Cell wall target fragment discovery using a low‐cost, minimal fragment library
FEBS Letters, EarlyView.LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan +5 more
wiley +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology, EarlyView.Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Медицинский вестник Юга России, 2010 Purpose: To investigate the effectiveness of recombinant VII activated coagulation factor in complex therapy of children with resistant coagulopathy caused by sepsis. Materials and Methods: 38 children from 2 months to 17 years old were investigated with
N. Bgane, A. Trembach
doaj
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Hereditary Factor VII deficiency in 17 Iraqi patients
مجلة كلية الطب, 2005 Background:
Waleed Abdelazez Omar, murtada Hasan
doaj +1 more source
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Pediatric cardiac surgery under cardiopulmonary bypass in factor VII deficiency
The Turkish Journal of Pediatrics, 2010 We present a case of an atrial septal defect repair under cardiopulmonary bypass in a child with factor VII deficiency. A four-year-old girl, with the diagnosis of secundum atrial septal defect, was referred to surgery. Coagulation tests showed an
Ozan Emiroğlu +3 more
doaj